Halopropane
Chemical compound
- None
- 3-Bromo-1,1,2,2-tetrafluoropropane
- 679-84-5
- 69623
- 62826
- 3DC4A5894W
- Interactive image
- C(C(C(F)F)(F)F)Br
InChI
- InChI=1S/C3H3BrF4/c4-1-3(7,8)2(5)6/h2H,1H2
- Key:YVWGMAFXEJHFRO-UHFFFAOYSA-N
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]
See also
- Aliflurane
- Roflurane
- Synthane
References
- ^ Webster NR, Galley HF (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
- ^ Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
- ^ Klein SL (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
- ^ Catcott EJ, Smithcors JF (1973). Progress in canine practice. American Veterinary Publications.
- v
- t
- e
General anesthetics (N01A)
| Phenols | |
|---|---|
| Barbiturates | |
| Benzodiazepines | |
| Opioids | |
| Arylcyclohexylamines | |
| Neuroactive steroids | |
| Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
